Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals (NASDAQ: KALV) announced positive topline data from a Phase 2 trial of KVD900, an oral treatment for hereditary angioedema (HAE) attacks. The trial showed statistically significant efficacy, with KVD900 resulting in a 15% rate of rescue medication use compared to 30% for placebo at 12 hours (p=0.001). Symptom relief onset was significantly faster with KVD900, taking 1.6 hours versus 9 hours for placebo (p<0.0001). No serious adverse events were reported, showcasing KVD900's favorable safety profile. A presentation of the trial data will be available on their website.
KalVista Pharmaceuticals (NASDAQ: KALV) reported no revenue for the second fiscal quarter ended October 31, 2020, down from $3.9 million the previous year, due to the expiration of the Merck Option Agreement. A net loss of $10.4 million, or $(0.58) per share, was observed, compared to a loss of $5.9 million, or $(0.33) per share, in the same quarter last year. The company completed patient treatment in a Phase 2 trial for KVD900, with data expected in Q1 2021. Additionally, an IND submission for KVD824 is anticipated in Q1 2021, aiming for a twice-daily oral treatment for hereditary angioedema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two investor conferences: Stifel 2020 Virtual Healthcare Conference on November 16 at 10:40 a.m. EST and Jefferies Virtual London Healthcare Conference on November 19 at 3:50 p.m. GMT. A live webcast of the presentations will be available on the company's website, with an audio archive accessible for 30 days afterward. The company focuses on small molecule protease inhibitors targeting diseases like hereditary angioedema and diabetic macular edema, with ongoing clinical trials for treatments such as KVD900 and KVD824.
KalVista Pharmaceuticals (NASDAQ:KALV) announced the completion of enrollment in its Phase 2 trial for KVD900, an oral treatment for hereditary angioedema (HAE), with data expected by year-end. Additionally, the company reported on KVD824, a twice-daily oral plasma kallikrein inhibitor for HAE prevention, which shows promising safety and tolerability. KalVista is also developing an oral Factor XIIa inhibitor as a new therapeutic option. An IND submission for KVD824 is planned for Q1 2021, with studies in the US and Europe.